免疫組織化学（IHC）の世界市場：洞察、競合情勢、市場予測：2030年

免疫組織化学（IHC）の市場規模は、2023年に25億6,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に7.64％のCAGRで拡大し、2030年には39億8,000万米ドルに達すると予測されています。免疫組織化学（IHC）市場は、HIV、B型肝炎、C型肝炎、インフルエンザ、ヒトパピローマウイルス（HPV）などの感染症患者の増加、がんの症例の増加、市場の主要企業による製品開発活動の活発化などにより大きな成長を遂げており、これらは2024年から2030年までの予測期間中に免疫組織化学（IHC）市場全体をエスカレートさせる要因として期待されています。

世界保健機関（WHO）の2024年の発表によると、2022年には世界で約3,900万人がHIV感染症に罹患していました。この情報源はまた、約3,750万人が成人（15歳以上）であり、約150万人が15歳未満の小児であると述べています。免疫組織化学は、HIV-1 p24タンパク質のような組織サンプル中のウイルス抗原を検出することにより、HIVの診断に不可欠であり、ウイルス量と組織病変の評価に役立ちます。

WHO 2024のデータによると、2022年には世界中で3億400万人がB型肝炎とC型肝炎に感染しています。B型肝炎の場合、免疫組織化学は肝生検でHBsAgのような表面抗原を同定することができ、肝病理や炎症あるいは線維化の程度を評価するのに役立ちます。C型肝炎では、コアタンパク質とNSタンパク質を可視化するために用いられ、肝組織におけるウイルス量と宿主反応を理解するのに役立ちます。このように、世界の感染症負担の増大は、正確で迅速な診断の必要性を生み出し、免疫組織化学市場を大きく牽引しています。

当レポートでは、世界の免疫組織化学（IHC）市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 免疫組織化学（IHC）市場レポートのイントロダクション

第2章 免疫組織化学（IHC）市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 免疫組織化学（IHC）市場の主な要因分析

• 免疫組織化学（IHC）の市場促進要因
• 免疫組織化学（IHC）の市場抑制要因と課題
• 免疫組織化学（IHC）の市場機会

第6章 免疫組織化学（IHC）市場におけるポーターのファイブフォース分析

第7章 免疫組織化学（IHC）市場評価

• 製品タイプ別
• 用途別
• エンドユーザー別
• 地域別

第8章 免疫組織化学（IHC）市場の企業と製品プロファイル

• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific
• PerkinElmer Inc.
• Danaher Corporation
• Merck KGaA
• Bio-Techne
• Genemed Biotechnologies, Inc.
• Abcam plc
• BD
• Bio SB, Inc.
• BioGenex
• Biocare Medical, LLC
• Diagnostic BioSystems Inc.
• ROCKLAND IMMUNOCHEMICALS, INC.
• Elabscience Biotechnology Inc.
• Sakura Finetek USA, Inc.
• CANDOR Bioscience GmbH
• NeoGenomics Laboratories

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Immunohistochemistry (IHC) Market in Global (2021-2030)
• Table 3: Immunohistochemistry (IHC) Market in Global by Product Type (2021-2030)
• Table 4: Immunohistochemistry (IHC) Market in Global by Application (2021-2030)
• Table 5: Immunohistochemistry (IHC) Market in Global by End-User (2021-2030)
• Table 6: Immunohistochemistry (IHC) Market in Global by Geography (2021-2030)
• Table 7: Immunohistochemistry (IHC) Market in North America (2021-2030)
• Table 8: Immunohistochemistry (IHC) Market in the United States (2021-2030)
• Table 9: Immunohistochemistry (IHC) Market in Canada (2021-2030)
• Table 10: Immunohistochemistry (IHC) Market in Mexico (2021-2030)
• Table 11: Immunohistochemistry (IHC) Market in Europe (2021-2030)
• Table 12: Immunohistochemistry (IHC) Market in France (2021-2030)
• Table 13: Immunohistochemistry (IHC) Market in Germany (2021-2030)
• Table 14: Immunohistochemistry (IHC) Market in United Kingdom (2021-2030)
• Table 15: Immunohistochemistry (IHC) Market in Italy (2021-2030)
• Table 16: Immunohistochemistry (IHC) Market in Spain (2021-2030)
• Table 17: Immunohistochemistry (IHC) Market in the Rest of Europe (2021-2030)
• Table 18: Immunohistochemistry (IHC) Market in Asia-Pacific (2021-2030)
• Table 19: Immunohistochemistry (IHC) Market in China (2021-2030)
• Table 20: Immunohistochemistry (IHC) Market in Japan (2021-2030)
• Table 21: Immunohistochemistry (IHC) Market in India (2021-2030)
• Table 22: Immunohistochemistry (IHC) Market in Australia (2021-2030)
• Table 23: Immunohistochemistry (IHC) Market in South Korea (2021-2030)
• Table 24: Immunohistochemistry (IHC) Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Immunohistochemistry (IHC) Market in the Rest of the World (2021-2030)
• Table 26: Immunohistochemistry (IHC) Market in the Middle East (2021-2030)
• Table 27: Immunohistochemistry (IHC) Market in Africa (2021-2030)
• Table 28: Immunohistochemistry (IHC) Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Immunohistochemistry (IHC) Market in Global (2021-2030)
• Figure 3: Immunohistochemistry (IHC) Market in Global by Product Type (2021-2030)
• Figure 4: Immunohistochemistry (IHC) Market in Global by Application (2021-2030)
• Figure 5: Immunohistochemistry (IHC) Market in Global by End-User (2021-2030)
• Figure 6: Immunohistochemistry (IHC) Market in Global by Geography (2021-2030)
• Figure 7: Immunohistochemistry (IHC) Market in North America (2021-2030)
• Figure 8: Immunohistochemistry (IHC) Market in the United States (2021-2030)
• Figure 9: Immunohistochemistry (IHC) Market in Canada (2021-2030)
• Figure 10: Immunohistochemistry (IHC) Market in Mexico (2021-2030)
• Figure 11: Immunohistochemistry (IHC) Market in Europe (2021-2030)
• Figure 12: Immunohistochemistry (IHC) Market in France (2021-2030)
• Figure 13: Immunohistochemistry (IHC) Market in Germany (2021-2030)
• Figure 14: Immunohistochemistry (IHC) Market in United Kingdom (2021-2030)
• Figure 15: Immunohistochemistry (IHC) Market in Italy (2021-2030)
• Figure 16: Immunohistochemistry (IHC) Market in Spain (2021-2030)
• Figure 17: Immunohistochemistry (IHC) Market in the Rest of Europe (2021-2030)
• Figure 18: Immunohistochemistry (IHC) Market in Asia-Pacific (2021-2030)
• Figure 19: Immunohistochemistry (IHC) Market in China (2021-2030)
• Figure 20: Immunohistochemistry (IHC) Market in Japan (2021-2030)
• Figure 21: Immunohistochemistry (IHC) Market in India (2021-2030)
• Figure 22: Immunohistochemistry (IHC) Market in Australia (2021-2030)
• Figure 23: Immunohistochemistry (IHC) Market in South Korea (2021-2030)
• Figure 24: Immunohistochemistry (IHC) Market in Rest of Asia-Pacific (2021-2030)
• Figure 25: Immunohistochemistry (IHC) Market in the Rest of the World (2021-2030)
• Figure 26: Immunohistochemistry (IHC) Market in the Middle East (2021-2030)
• Figure 27: Immunohistochemistry (IHC) Market in Africa (2021-2030)
• Figure 28: Immunohistochemistry (IHC) Market in South America (2021-2030)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Marker Opportunities
• Figure 32: PORTER'S Five Force Analysis

Immunohistochemistry (IHC) Market by Product Type (Instruments, Reagents & Kits, and Services), Application (Diagnostic, Research, and Forensic), End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing instances of infectious diseases and increasing product developmental activities worldwide

The immunohistochemistry (IHC) market was valued at USD 2.56 billion in 2023, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 3.98 billion by 2030. The immunohistochemistry (IHC) market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B and C, influenza, and human papillomavirus (HPV), increasing instances of cancer, rising product developmental activities by market key players, among others that are factors expected to escalate the overall immunohistochemistry (IHC) market during the forecast period from 2024 to 2030.

Immunohistochemistry (IHC) Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years. Immunohistochemistry is essential in HIV diagnostics by detecting viral antigens in tissue samples, such as the HIV-1 p24 protein, which helps assess viral load and tissue involvement.

Data from the WHO 2024, stated that 304 million people were infected by hepatitis B and C across the world in the year 2022. The same source further stated that out of these, 254 million were afflicted by hepatitis B and 50 million were affected by hepatitis C. For hepatitis B, immunohistochemistry can identify surface antigens like HBsAg in liver biopsies, aiding in the assessment of liver pathology and the degree of inflammation or fibrosis. In hepatitis C, it is used to visualize core proteins and NS proteins, assisting in understanding viral load and the host response in liver tissues. Thereby growing burden of infectious diseases worldwide will create need for accurate and rapid diagnostics significantly drives the market for immunohistochemistry.

The Global Cancer Observatory (2024), estimated that the new instances of cancer globally would reach from 20 million to 24.1 million by the year 2030. It stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases. For cancer amid rising global cases immunohistochemistry detects specific tumor markers in tissue samples, aiding classification and treatment decisions by assessing biomarkers like hormone receptors and PD-L1. This enhances personalized medicine and improves patient outcomes resulting into increased demand for immunohistochemistry.

Additionally, in July 2021, Agilent Technologies Inc.'s PD-L1 IHC 22C3 pharmDx assay was labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

Therefore, the factors stated above collectively will drive the overall immunohistochemistry market growth.

However, specificity & sensitivity issues associated with immunohistochemistry, availability of alternative options in the market, and others may limit their end-user base, thus acting as key constraints limiting the growth of the immunohistochemistry market growth.

Immunohistochemistry (IHC) Market Segment Analysis:

Immunohistochemistry (IHC) Market by Product Type (Instruments, Reagents & Kits, and Services), Application (Diagnostic, Research, and Forensic), End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the immunohistochemistry market, the reagents & kits category is expected to have a significant revenue share in the year 2023. This is due to various features and applications offered by these devices.

Immunohistochemistry kits and reagents are essential tools for detecting specific antigens in tissue sections, utilizing antigen-antibody binding to visualize protein expression. Key features of immunohistochemistry kits and reagents include optimized, ready-to-use primary and secondary antibodies, detection systems with chromogenic or fluorescent labels, and buffers that enhance staining quality.

Immunohistochemistry kits and reagents are widely used in pathology for cancer diagnostics, where they help identify tumor subtypes and prognostic markers such as HER2, ER, and PR in breast cancer. They are also applied in the detection of infectious agents, such as in tuberculosis and viral infections, and in the research of neurological diseases, allowing visualization of protein aggregates like amyloid plaques in Alzheimer's disease.

Moreover, introduction of new products in this category will further drive the market for same. For example in March 2023, Aptamer Group launched a new reagent solution, Optimer-Fc for use in automated immunohistochemistry workflows.

Therefore, the widespread uses and various advantages of reagents & kits enhance performance and usability, solidifying the significant impact on the growth of the overall immunohistochemistry market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall immunohistochemistry (IHC) market:

Among all the regions, North America is expected to dominate the immunohistochemistry (IHC) market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This domination is due to the growing burden of cancer cases in the region, rise in tuberculosis instances, growing product developmental activities, presence of key manufacturers, among others are factors that are expected to fuel the market for immunohistochemistry market in the North America region during the forecast period from 2024 to 2030.

Global Cancer Observatory (2024), estimated that 3.83 million new case of cancer will be diagnosed by 2045 in North American region.

Public Health Agency of Canada (2024), stated that in 2022, there were 1,971 active tuberculosis cases in Canada. In tuberculosis, molecular diagnostics enable rapid and accurate identification of mycobacterium tuberculosis, as well as the detection of drug resistance, improving timely diagnosis and treatment.

In cancer, immunohistochemistry helps classify tumors, assess biomarkers like HER2, and guide treatment whereas in tuberculosis, it detects mycobacterial antigens in tissue biopsies, aiding in diagnosis alongside molecular tests. Since cancer instances are rising there is increasing demand for personalized medicine and the adoption of immunohistochemistry in infectious disease diagnostics, such as tuberculosis, further drives the immunohistochemistry market.

Immunohistochemistry enhances precision in both disease detection and treatment selection, ultimately improving patient outcomes. Additionally, the presence of key manufacturers in the region and their strategic business activities will also contribute to the molecular diagnostic market growth.

Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for Immunohistochemistry (IHC). For example, in April 2021, Roche received the US FDA approval for the VENTANA MMR RxDx Panel, the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly).

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American immunohistochemistry market.

Immunohistochemistry (IHC) Market key players:

Some of the key market players operating in the immunohistochemistry (IHC) market include F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne, Genemed Biotechnologies, Inc., Abcam plc, BD, Bio SB, Inc., BioGenex, Biocare Medical, LLC, Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories, and others.

Recent Developmental Activities in the Immunohistochemistry (IHC) Market:

• In August 2024, Agilent Technologies Inc., announced that it received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032). It is an immunohistochemistry assay used to detect MAGE-A4 expression in formalin-fixed paraffin-embedded (FFPE) synovial sarcoma tissue.
• In November 2023, Biocare Medical, a leading provider in the immunohistochemistry sector, launched their newest innovation ARC (Antigen Retrieval Chamber).
• In March 2021, Roche launched the DISCOVERY Green HRP kit. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens.

Key Takeaways from the Immunohistochemistry (IHC) Market Report Study

• Market size analysis for current immunohistochemistry (IHC) market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the immunohistochemistry (IHC) market.
• Various opportunities available for the other competitors in the immunohistochemistry (IHC) market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current immunohistochemistry (IHC) market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for immunohistochemistry (IHC) market growth in the coming future?

Target Audience who can be benefited from this immunohistochemistry (IHC) Market Report Study

• Immunohistochemistry (IHC) product providers
• Research organizations and consulting companies
• Immunohistochemistry (IHC)-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in immunohistochemistry (IHC)
• Various end-users who want to know more about the immunohistochemistry (IHC) market and the latest developments in the immunohistochemistry (IHC) market

Frequently Asked Questions for the Immunohistochemistry (IHC) Market:

1. What are immunohistochemistry (IHC)?

• The immunohistochemistry is a technique that uses antibodies to check for certain antigens (markers) in a sample of tissue. The antibodies are usually linked to an enzyme or a fluorescent dye.

2. What is the market for immunohistochemistry (IHC)?

• The immunohistochemistry (IHC) market was valued at USD 2.56 billion in 2023, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 3.98 billion by 2030.

3. What are the drivers for the immunohistochemistry (IHC) market?

• The immunohistochemistry (IHC) market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B and C, influenza, and human papillomavirus (HPV), increasing instances of cancer, rising product developmental activities by market key players, among others that are factors expected to escalate the overall immunohistochemistry (IHC) market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the immunohistochemistry (IHC) market?

• Some of the key market players operating in immunohistochemistry (IHC) include F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne, Genemed Biotechnologies, Inc., Abcam plc, BD, Bio SB, Inc., BioGenex, Biocare Medical, LLC, Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories, and others.

5. Which region has the highest share in the immunohistochemistry (IHC) market?

North America is expected to dominate the overall immunohistochemistry market during the forecast period from 2024 to 2030. This domination is due to the growing burden of cancer cases in the region, rise in tuberculosis instances, growing product developmental activities, presence of key manufacturers, among others are factors that are expected to fuel the market for immunohistochemistry market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Immunohistochemistry (IHC) Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Immunohistochemistry (IHC) Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Immunohistochemistry (IHC) Market Key Factors Analysis

• 5.1. Immunohistochemistry (IHC) Market Drivers
  • 5.1.1. Growing instances of infectious diseases
  • 5.1.2. Increasing product developmental activities worldwide
  • 5.1.3. Rising instances of chronic disorders
• 5.2. Immunohistochemistry (IHC) Market Restraints and Challenges
  • 5.2.1. Specificity and sensitivity issues associated with immunohistochemistry (IHC)
  • 5.2.2. Availability of alternative options in the market
• 5.3. Immunohistochemistry (IHC) Market Opportunities
  • 5.3.1. Strategic business activities by the global as well as regional manufacturers
  • 5.3.2. Integration with digital pathology and AI

6. Immunohistochemistry (IHC) Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Immunohistochemistry (IHC) Market Assessment

• 7.1. By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Kits
  • 7.1.3. Services
• 7.2. By Application
  • 7.2.1. Diagnostic
  • 7.2.2. Research
  • 7.2.3. Forensic
• 7.3. By End-User
  • 7.3.1. Hospitals & Diagnostic Laboratories
  • 7.3.2. Academic & research Institutes
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.3.3. India Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Immunohistochemistry (IHC) Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Immunohistochemistry (IHC) Market Size in USD million (2021-2030)

8. Immunohistochemistry (IHC) Market Company and Product Profiles

• 8.1. F. Hoffmann-La Roche Ltd.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Agilent Technologies, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Bio-Rad Laboratories, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Thermo Fisher Scientific
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. PerkinElmer Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Danaher Corporation
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Merck KGaA
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Bio-Techne
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Genemed Biotechnologies, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Abcam plc
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. BD
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Bio SB, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. BioGenex
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Biocare Medical, LLC
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Diagnostic BioSystems Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. ROCKLAND IMMUNOCHEMICALS, INC.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Elabscience Biotechnology Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Sakura Finetek USA, Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. CANDOR Bioscience GmbH
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. NeoGenomics Laboratories
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us